Jan Beck

Chief Operating Officer at Mozart Therapeutics, Inc.

Health Technology

Profile

Jan Beck is currently the Director at Life Science Washington and a Member at the Association of Washington Business.
He is also the Chief Operating Officer at Mozart Therapeutics, Inc. starting from 2022.
Previously, he worked as the Head-Research & Development Operations at Lyell Immunopharma, Inc.

Jan Beck active positions

Companies	Position	Start
Mozart Therapeutics, Inc. Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.	Chief Operating Officer	2022-03-20
Life Science Washington	Director/Board Member	-
Association of Washington Business	Corporate Officer/Principal	-

All active positions of Jan Beck

Former positions of Jan Beck

Companies	Position	End
LYELL IMMUNOPHARMA, INC.	Corporate Officer/Principal	-

See the detail of Jan Beck's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jan Beck's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
LYELL IMMUNOPHARMA, INC.	Health Technology

Private companies	3
Mozart Therapeutics, Inc. Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.	Health Technology
Life Science Washington
Association of Washington Business

See company connections